Atlas Trials

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Clinical trial NCT02819271 · COMPLETED

Trial details

NCT number
NCT02819271
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Heart Failure
Start date
2014-02-01
Primary completion
2014-04-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.